Proforms of gastrointestinal peptides are cleaved at paired basic residues into intermediate forms. Paired basic residues at the Cterminal then are excised by carboxypeptidases before the peptide is amidated. An obese mouse, called Cpe fat /Cpe fat , has a missense mutation in carboxypeptidase E (CPE) with no pancreatic CPE activity and a reduced processing of pancreatic proinsulin to insulin. The purpose of this study was 1) to look for the presence of CPE in the antrum of the stomach, duodenum, and colon in the Cpe fat /Cpe fat mouse; 2) to determine whether CPE is involved in the processing of progastrin (Pro-G) to its carboxyl-terminal amidated form; and 3) to determine whether a decrease in amidated gastrin results in an upregulation of stomach gastrin messenger RNA (mRNA) levels. In Cpe fat /Cpe fat mice, CPE activity was absent in the antrum and colon. In Cpe fat /Cpe fat mice, amidated gastrin levels were reduced significantly. Levels of the precursor for amidated gastrin (gastrin-Gly-ArgArg) were markedly elevated. Gastrin mRNA levels were increased approximately 2-fold over the levels in Cpe fat /Cpe fat mice. These results indicate that CPE is needed for processing progastrin to gastrin in the stomach and that amidated gastrin exerts an inhibitory feedback effect on gastrin mRNA levels.
determine whether a decrease in amidated gastrin results in an upregulation of stomach gastrin messenger RNA (mRNA) levels. In Cpe fat /Cpe fat mice, CPE activity was absent in the antrum and colon. In Cpe fat /Cpe fat mice, amidated gastrin levels were reduced significantly. Levels of the precursor for amidated gastrin (gastrin-Gly-ArgArg) were markedly elevated. Gastrin mRNA levels were increased approximately 2-fold over the levels in Cpe fat /Cpe fat mice. These results indicate that CPE is needed for processing progastrin to gastrin in the stomach and that amidated gastrin exerts an inhibitory feedback effect on gastrin mRNA levels. (Endocrinology 138: 1959 -1963, 1997) G ASTRIN IS an endocrine peptide localized primarily in the antral G cells of the stomach mucosa (1). One of the major functions of gastrin is the regulation of gastric acid secretion by the parietal cells of the stomach (1) . Gastrin also has trophic effects on the gastrointestinal tract and pancreas (2) (3) (4) (5) (6) ; it affects stomach muscle contraction (7) , and it stimulates fractional sodium excretion by the kidney while increasing renal plasma flow (8) . Gastrin is processed posttranslationally to intermediate forms, gastrin-Gly-Arg-Arg and gastrin-Gly (9) . Although amidation of the COOH-terminal of gastrin is thought to be essential for biological activity (10) , there is recent evidence to show that gastrin-Gly can stimulate acid secretion (11) and can have a trophic action (12, 13) . In addition, although there is no evidence showing that gastrin-Gly-Arg-Arg itself is active biologically, a recent report indicates that elevated levels of progastrin can increase the bromodeoxyuridine labeling index of the colon (14) .
An obese mouse model (Cpe fat /Cpe fat ) has been described that has hyperproinsulinemia and late-onset obesity (15) . These Cpe fat /Cpe fat mice have a missense mutation in carboxypeptidase E (CPE), with marginal pancreatic CPE-like activity and a reduced capacity to process pancreatic proinsulin to insulin. The missense mutation converts Ser 202 into Pro, a change that eliminates CPE activity (16) . CPE is a processing enzyme involved in the excision of paired basic residues remaining at the carboxyl-terminus after cleavage by a prohormone convertase of many endocrine and neuroendocrine peptides (17) . Whether CPE is involved in processing progastrin to biologically active amidated gastrin is not known. A deficiency of CPE activity in the stomach may result in the excessive production of intermediate gastrin peptides with C-terminal dibasic residue extensions. In addition, it is conceivable that gastrin messenger RNA (mRNA) expression in the stomach is simultaneously increased as a result of the reduced processing of progastrin to biologically active COOH terminal-amidated gastrin and lower systemic circulatory levels of amidated gastrin. In the present study, we examined the processing of progastrin to gastrin in the antrum of the stomach, gastrointestinal CPE activity, and antral gastrin mRNA levels of Cpe fat /Cpe fat mice. The specific detection of amidated gastrin and its proforms was facilitated in part by the availability of specific and sensitive antisera for amidated gastrin and gastrin-Gly-Arg-Arg (18, 19) .
Materials and Methods Animals
Cpe fat /Cpe fat and control (Cpe fat /ϩ; ϩ/ϩ) mice were produced in a research animal colony by one of the authors (E.L.) at the Jackson Laboratory (Bar Harbor, ME). The mice were weaned on Old Guilford Diet 96WA (Emory Morse Co., Guilford, CT) and maintained on that diet until shipment to University of Texas Medical Branch (Galveston, TX). At the University of Texas Medical Branch, mice were maintained on Teklad rodent diet until death. Mice were acclimated to local housing conditions for at least 1 week and were maintained in an air-conditioned (23 Ϯ 2 C) and light-regulated (lights on 0600 -1800 h) vivarium. All mice had free access to chow and tap water. Cpe fat /Cpe fat mice were identified by genetic markers and, phenotypically, by the development of obesity. Mice were killed by decapitation in the ad libitum-fed condition. The mean body weights Ϯ sem of control and Cpe fat /Cpe fat mice were 29 Ϯ 2 and 37 Ϯ 3 g, respectively. The ages of Cpe fat /Cpe fat and control mice ranged from 2-19 months; Cpe fat /Cpe fat and control mice were agematched. The brain, pancreas, antrum of the stomach, duodenum, and colon were removed. Pancreatic islets were prepared by infusion of the common bile duct with a collagenase solution and harvested by hand under a dissecting microscope. The gastrointestinal tract was cleaned carefully of food material or feces. The antrum was bisected; half was frozen for analyses of carboxypeptidases (CPs), and the remaining half was homogenized immediately in distilled water (1:10, wt/vol) and then boiled for 20 min. Boiled extracts were stored frozen until assayed by the various gastrin RIAs. In a separate series of Cpe fat /Cpe fat and control mice, the entire antrum was removed and homogenized in a RNA extraction solution for preparation of total cellular RNA.
Assays

C-Terminal amidated gastrin and gastrin-Gly-Arg-Arg RIAs.
A double antibody RIA procedure (20) was used to specifically measure C-terminal amidated gastrin. This RIA uses an antiserum (5135, provided by the Center for Ulcer Research and Education, University of California-Los Angeles, Digestive Diseases Center Antibody Core) that recognizes only C-terminally amidated gastrin and cholecystokinin (CCK) and does not cross-react with C-terminally extended forms of either peptide (19) . CCK is not present in the antrum (21) , so detection of CCK is not a consideration. The sensitivity and ID 50 (50% inhibition of bound [
125 I]gastrin) for amidated gastrin are 6 and 50 pg/tube, respectively. The antiserum was used at an initial dilution of 1:50,000. Gastrin-Gly-Arg-Arg was measured by a double antibody RIA using an antiserum that is highly specific for gastrin-Gly-Arg-Arg (antiserum GL-9, gift from C. Dickinson, University of Michigan, Ann Arbor, MI) (18) . This antiserum does not recognize amidated CCK-8, amidated gastrin. or gastrin-Gly; the cross-reactivity of this antiserum with gastrin-Gly-Arg and gastrins beyond the Gly-Arg-Arg residues is less than 10% (18) . The sensitivity and ID 50 for gastrin-Gly-Arg-Arg are 40 and 300 pg/tube, respectively. A synthetic peptide (YGWMDFGRR), iodinated by the chloramine-T method, was used as the iodinated ligand and standard. The antiserum was used at an initial dilution of 1:3,000.
Assay for CPE-like enzymes.
Gastrointestinal tissue extracts were prepared and analyzed enzymatically for CPD/CPE activities as described previously (22) . In brief, tissues were harvested, frozen on dry ice, and stored at Ϫ20 C. Tissues later were homogenized in 0.2-2 ml 0.1 m sodium acetate (NaAc; pH 5.5) containing 1 mm phenylmethylsulfonylfluoride. Protein concentrations were determined with the Bradford assay, using BSA as a standard. For the carboxypeptidase assay, 25 l of the homogenate or 25 ml of a 1:10 dilution were combined with 200 m dansyl-Phe-Ala-Arg substrate, including 50 mm NaAc (pH 5.0) and 0.01% Triton X-100 (23) in a final volume of 250 l. Tubes containing either 1 mm CoCl 2 or 1 mm guanidino-ethylmercaptosuccinic acid (GEMSA) were included. After incubation at 37 C for 30 -60 min, 100 l 0.5 m HCl and 2 ml chloroform were added, and the tubes were mixed and then centrifuged at 500 ϫ g for 2 min. The amount of product was determined by measuring the fluorescence in the lower (chloroform) layer; excitation was 350 nm, and emission was 500 nm. CP activity is defined as the difference between activity measured in the presence of Co 2ϩ , which activates CPE, and that in the presence of GEMSA, which inhibits CPE. These conditions are not specific for CPE because Co 2ϩ activates, and GEMSA inhibits, other metallocarboxypeptidases (24) .
The enzymatic properties of affinity-purified gastrointestinal tissue extracts were determined in an assay similar to that described above, except that 50 mm NaAc (pH 5.5) or Tris-Cl (pH 7.4) was used, and the tubes contained various ions or inhibitors instead of Co 2ϩ or GEMSA. Samples were preincubated with inhibitors for 15 min at 4 C, the substrate was added, and the tubes were incubated for an additional 1 h at 37 C. CP activity was calculated as the difference in fluorescence between the tubes containing enzyme and those with only buffer and substrate and was expressed as a percentage of the control tube containing enzyme, buffer, and substrate, but without divalent ions or inhibitors.
Purification of CPE-like enzymes by substrate affinity chromatography. Gastrointestinal tissue homogenates were combined with Triton X-100 (final concentration, 1%) and NaCl (final concentration, 1 m). Homogenates were mixed and centrifuged for 30 min at 50,000 ϫ g at 4 C, and the supernatants were applied to a p-aminobenzoyl-Arg Sepharose 6B column (23, 24) . Columns (0.5-ml bed volume) were washed with 30 ml 1 m NaCl and 1% Triton X-100 in 50 mm NaAc (pH 5.5) and rinsed with 5 ml 10 mm NaAc (pH 5.5). CPE was eluted with 3.6 ml 50 mm Tris-Cl (pH 8.0) including 100 mm NaCl and 0.01% Triton X-100 (elute 1). The column then was eluted with 3.6 ml 5 mm Arg in the same buffer (elute 2). CP activity was determined as described above.
Western blot of purified proteins. Aliquots of the affinity column elute fractions were dried in a vacuum centrifuge, resuspended in polyacrylamide sample buffer (containing 1% SDS), heated to 95 C for 5 min, and loaded onto a 10% denaturing polyacrylamide gel. Electrophoresed proteins then were transferred to a nitrocellulose membrane and probed with an antiserum generated against a synthetic nine-residue fragment corresponding to the C-terminus of the full-length mouse CPE. This antiserum was used at final dilution of 1:1000.
Measurement of gastrin mRNA. Total cellular RNA was prepared by homogenization of tissues in 4 m guanidine thiocyanate [including 25 mm sodium citrate (pH 7.0), 0.5% sodium N-lauroylsarcosine, and 0.1 m 2-mecaptoethanol] immediately after dissection. Samples then were centrifuged (18 h, 30,000 rpm) through a CsCl cushion (2 ml, 5.7 m) as described previously (25) . RNA concentrations in the samples were quantitated by absorbance at 260 nm. Gastrin mRNA levels were analyzed by means of Northern (30 g) and slot blot analyses (2.5 g). For Northern blot analysis, total cellular RNA was separated by electrophoresis on a 1% denaturing agarose gel (25) . RNA then was transferred to a nitrocellulose membrane. After an overnight prehybridization at 65 C, hybridization with 32 P-labeled gastrin complementary RNA probe was carried out for 24 h. The antisense complementary RNA probe was generated by means of SP6 RNA polymerase-directed transcription of a plasmid containing the rat gastrin with the use of [␣-
32 P]CTP and the Riboprobe Gemini System (Promega, Madison, WI) according to the directions contained in the kit. The rat gastrin complementary DNA was provided by S. Brand (26) . Membranes were hybridized with a rat 18S ribosomal probe to monitor RNA loading. The 18S probe was labeled using a random primed protocol (Promega) with [ 32 P]deoxy-ATP and hybridized at 45 C. Autoradiographs were subjected to densitometric scanning (Visage 60, Bio-Image, Ann Arbor, MI) quantification. The relative amounts of each mRNA species were calculated in arbitrary densitometric units.
Statistical analysis
Results are the mean Ϯ se. Data were analyzed by either Student's t test or a one-way classification ANOVA followed by the Newman-Keuls test where pertinent. Differences with P Ͻ 0.05 were considered significant.
Results
In the Cpe
fat /Cpe fat antrum, amidated gastrin levels are approximately 3-fold lower (P Ͻ 0.05) than those in control mice (Table 1) . In contrast, gastrin-Gly-Arg-Arg levels are approximately 670-fold higher in Cpe fat /Cpe fat mice than those in control mice. The ratio of G/gastrin-Gly-Arg-Arg is approximately 3600-fold greater in Cpe fat /Cpe fat mice than in control mice.
In Cpe fat /Cpe fat mice, antral gastrin mRNA levels are elevated significantly (P Ͻ 0.05; Table 1 and Fig. 1 ). They are approximately 172% of control levels.
Gastrointestinal tissues contain Co 2ϩ -activated and GEMSA-inhibited carboxypeptidase activity (Table 2) . In control mice, high levels of CPE-like activity are detected in the pancreatic islets, and lower levels are detected in the duodenum, antrum, and colon. 
/Cpe
fat and control mice do not differ statistically (P Ͼ 0.05).
The finding that CPE-like activity is not depressed in some Cpe fat /Cpe fat mouse tissues compared to those in the corresponding control mouse tissues suggests that either the point mutation affects the enzyme differently in the various tissues or other enzymes contribute to the CPE-like activity. To examine these possibilities, the antral and colonic extracts were fractionated on a substrate affinity column. This had been shown previously to separate CPE from CPD (24) . In the Cpe fat /Cpe fat antrum and colon, the amount of CPE (elute 1) is reduced significantly compared to those in control antrum and colon (Table 3 ). The amounts of CPD activity (elute 2) in control and Cpe fat /Cpe fat antrum and colon do not differ significantly.
Western blot analysis of affinity-purified material from antrum, colon, and duodenum showed (Fig. 2) (Fig. 2) . Immunoreactive CPE is not detectable in the duodenum of control mice.
The small amount of CP activity detected in the elute 1 fraction from the colon of Cpe fat /Cpe fat mice does not have the same enzymatic properties as purified CPE (Table 4) . Whereas purified CPE is active optimally at pH 5.5 and is inhibited potently by GEMSA, HgCl 2 , and para-chloromercuriphenyl sulfonate, the elute 1 activity from Cpe fat /Cpe fat colon is partially inhibited by these compounds and is more active at pH 7.4 than at pH 5.5 ( Table 4 ). The activities in the elute 2 fraction from both control and Cpe fat /Cpe fat mouse colon are similar, generally, to each other and to purified brain CPD (Table 4 ). The differences between CPE and CPD are similar to those reported previously (24) .
Discussion
The results of the present study confirm and extend the original report that described the absence of CPE-like activity in the endocrine pancreas of the Cpe fat /Cpe fat mouse (15) . The present study indicates that there is no active CPE in the gastrointestinal tract (stomach, duodenum, and colon) of the Cpe fat /Cpe fat mouse, as immunoreactive CPE in these tissues of the Cpe fat /Cpe fat mouse was not detected after purification using a substrate affinity column. CPE does not occur in detectable levels in the duodenum. These tissues show a small amount of CP activity in the affinity column fractions corresponding to CPE; however, the enzymatic properties are not identical to those of CPE. The earlier report indicated that CPE-like activity was marginal, but not eliminated completely, in Cpe fat /Cpe fat mouse pituitary and pancreatic islets (15) . This earlier analysis of CPE-like activity did not consider the possibility that other CPs contributed to the low levels of CPE-like activity in the pancreas and pituitary of Cpe Previous to the discovery of CPD (24), CPE was the only described metallocarboxypeptidase with an acidic pH optimum. This is the primary criterion used to distinguish CPE from other CPs (M, N, B, and A) (22) . Our results show that a large portion of the CPE-like activity in the antrum and colon is actually CPD, based on the separation of the enzyme activities over the substrate affinity column. Marginal amounts of CPE-like activity are detected in the high pH elutes from the affinity columns of the Cpe fat /Cpe fat mouse antrum and colon. This activity is not CPE, based on its immunoreactivity and enzyme properties and may represent a novel CP. In any case, this activity is marginal compared to the levels of CPE in control mouse tissues and in control and Cpe fat /Cpe fat tissues. The absence of active CPE in the Cpe fat /Cpe fat mouse results in a substantial reduction in the stomach level of the fully processed gastrin (i.e. COOH-terminal amidated gastrin). As expected, the level of gastrin-Gly-Arg-Arg is elevated dramatically. Whether circulating levels of C-terminal amidated gastrin are reduced with a consequent stomach hypoacidity was not examined in the present study, and it would be intriguing to determine whether Cpe fat /Cpe fat mice develop hypergastrinemia (C-terminal amidated gastrin) by treatment with acid inhibitory drugs (omeprazole). If omeprazole-treated Cpe fat /Cpe fat mice develop C-terminal amidated hypergastrinemia not distinguishable from that in control mice, this would suggest that alternate efficient processing pathways can replace the CPE pathway. Progastrin requires a prohormone convertase to cleave at a pair of basic residues, followed by a CP to excise C-terminal basic residues, and then amidation of the C-terminus by peptidylglycine-␣-amidating monooxygenase (9) . The levels of the C-terminally extended gastrin precursor were approximately 670-fold higher in the Cpe fat /Cpe fat mouse stomach than those in control mice. These results are similar to those found previously for proinsulin processing in the pancreatic islets of the Cpe fat / Cpe fat mouse (15) . In islets, C-terminally extended insulin was undetectable in the control mice, but was equal to the level of correctly processed insulin in the Cpe fat /Cpe fat mouse (15) . Recently, CPE activity has been found to be absent in Cpe fat /Cpe fat mouse brain (27) , and the processing of dynorphin (27) and that of neurotensin (28) are altered. Together, these results indicate that the CPE deficiency in the Cpe fat / Cpe fat mice results in an accumulation of peptides with Cterminal basic residues and a smaller, but significant, decrease in the levels of appropriately processed peptides.
The finding that some C-terminal processing of gastrin continues in the antrum of Cpe fat /Cpe fat mice suggests an alternative CP exists. CPD may contribute to the processing of these peptides. CPD is in the secretory pathway, based on the studies of the duck homolog of CPD (29, 30) and the recent studies showing that mouse CPD is present in the trans Golgi network (Varlamov, O., L. Song, and L. Fricker, unpublished). It is possible that other CPs present in the secretory pathway may contribute to peptide processing. Alternatively, endopeptidases may excise the peptide precursors to the N-terminal side of the basic residues, giving rise to the C-terminally processed peptide without the need for a CP. Prohormone convertases 1/3 and 2 do not cleave to the N-terminal side of the basic residues within the cleavage site (31, 32) ; however, other enzyme activities have been reported that can perform this cleavage (33, 34 ) lends support to this idea. In the present study, we did not determine whether the increase in steady state gastrin mRNA levels is due to increased antral gastrin gene transcription rates or to increased mRNA stability. Although speculative, amidated gastrin may regulate its own mRNA expression in a negative fashion by its direct feedback at the stomach on gastrin-producing G cells or on somatostatin-producing D cells. Somatostatin can inhibit gastrin release from the stomach (35) , and a decrease in circulating gastrin may decrease the inhibitory input of stomach somatostatin on G cells. Immunoelectron microscopy has shown the presence of the CCK-B (gastrin) receptor on endocrine cells of the guinea pig stomach (36) . Parenthetically, the idea that amidated gastrin down-regulates its own mRNA levels can be tested by the administration of exogenous amidated gastrin to Cpe fat /Cpe fat mice and the monitoring of antral gastrin mRNA levels. 
